Reagents were from ThermoFisher (Invitrogen), unless stated otherwise. Patient information is listed in Supplementary Figure 2A . Reprogramming of iPSCs from patients SCA14-1 and SCA14-2 using SeVdp(KOSM)302L Sendai virus system (Nishimura et al., 2011; Nishimura et al., 2013) was carried out as previously described (Watson et al., 2018). Reprogramming of skin fibroblasts from patients PRKCG01 and PRKCG02 was performed using the CytoTune®-iPS 2.0 Sendai Reprogramming Kit according to manufacturer's protocols. Briefly, patients' skin fibroblasts were thawed and expanded. Two days prior to viral transduction, the fibroblasts were detached and seeded at a range of densities on 12-well plates (0.75x105, 1x105, 1.25x105, 1.5x105, 2.0x105) and grown for two days to 90% confluency. Sendai virus was added to fibroblasts on day 0 at a multiplicity of infection (MOI) of 3 per 1.0x10 5 cells and incubated overnight. Virus was removed the next day. A well of untransfected fibroblasts was kept for each density for monitoring cell division. Transduced fibroblasts were cultured in fibroblast medium [ADMEM, Gibco; 10% foetal calf serum; 1% Glutamax; Gibco; 1% penicillin/streptomycin (P/S)]. 8000 reprogrammed cells per ml were transferred to a layer of mouse embryonic feeder cells (CF1 MEF) (Merck) on 0.1% gelatin-coated 6-well plates and cultured in KOSR medium [KnockOut Dulbecco's modified Eagle's medium (DMEM), 10% KnockOut Serum Replacement; 0.1% Non-Essential Amino Acids, 2 mM GlutaMax-I, 0.5 mM β-mercaptoethanol, 10 ng/ml Basic Fibroblast Growth Factor (R&D), 1% P/S] on day 7. The remaining cells were pelleted as positive control for the Sendai virus clearance assay. Half of the media were changed every two days until day 13. MEF cells were set up in T-75 flasks on day 7 and cultured in KOSR medium. The medium was collected every day for seven days as conditioned medium to feed iPSCs on feeder cells after sterilization. Reprogrammed cells were fed with conditioned medium supplemented with 10 ng/ml bFGF for around 2 weeks. Colonies that emerged at around day 26 were ready for manual passaging onto Matrigel (Corning)-coated 12-well plates for culture under feeder-free condition. For passage number 5 to 8, two vials of iPSCs (2-3x10 6 cells each) were frozen and the remaining well were expanded. Three clones of iPSCs were expanded in mTeSR medium (StemCell Technologies) supplemented with 1% P/S for three to four weeks until reaching six 10-cm dishes. Cells were detached using 0.5 mM EDTA or pre-warmed TrypLE. iPSCs were then frozen in freezing medium containing 10% DMSO and 30% foetal bovine serum (2-3x10 6 cells per vial), and then stored in liquid nitrogen for long term. Three cell pellets per clone were prepared and stored at -80 o C at the time of freezing for genomic DNA and total RNA preparation. iPSC expansion and cell pelleting was repeated if clones showed abnormal karyotypes. DNA was prepared using DNeasy Blood & Tissue Kit (Qiagen). Genome integrity analysis was performed using Illumina Human OmniExpress-24.v1.1 DNA Analysis Kit (WG-315-1101). The results were analysed using KaryoStudio 1.3 and GenomeStudio software (Illumina). iPSC line SNP profiles were compared to the original pool of fibroblasts, which confirmed the identity of the iPSC to the original fibroblasts. iPSC lines were also assessed for pluripotency markers by flow cytometry as previously described (Watson et al., 2018). iPSC lines tested negative for mycoplasma using MycoAlert (Lonza). RT-qPCR was performed to confirm the clearance of Sendai virus and transgenes. Genotypes of human dermal fibroblasts (HDF) and iPSCs were confirmed by Sanger sequencing. Regions of exon 1 and exon 4 of the PRKCG gene were amplified using the Expand High Fidelity PCR System (Sigma). PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) and sent for Sanger sequencing. Primers are listed in Supplementary Table 2. 2 Supplementary Figure 1 
o C at the time of freezing for genomic DNA and total RNA preparation. iPSC expansion and cell pelleting was repeated if clones showed abnormal karyotypes. DNA was prepared using DNeasy Blood & Tissue Kit (Qiagen). Genome integrity analysis was performed using Illumina Human OmniExpress-24.v1.1 DNA Analysis Kit (WG-315-1101) . The results were analysed using KaryoStudio 1.3 and GenomeStudio software (Illumina). iPSC line SNP profiles were compared to the original pool of fibroblasts, which confirmed the identity of the iPSC to the original fibroblasts. iPSC lines were also assessed for pluripotency markers by flow cytometry as previously described (Watson et al., 2018) . iPSC lines tested negative for mycoplasma using MycoAlert (Lonza). RT-qPCR was performed to confirm the clearance of Sendai virus and transgenes. Genotypes of human dermal fibroblasts (HDF) and iPSCs were confirmed by Sanger sequencing. Regions of exon 1 and exon 4 of the PRKCG gene were amplified using the Expand High Fidelity PCR System (Sigma). PCR products were purified using the QIAquick PCR Purification Kit (Qiagen) and sent for Sanger sequencing. Primers are listed in Supplementary Reprogramming and quality control of SCA14 iPSCs (A) A list of patient iPSC lines generated and control iPSC lines included in this study. Age reflects age at which skin biopsy was taken. (B) Representative phase-contrast images of patient iPSC clones cultured on Matrigel-coated surface, which showed normal iPSC morphology. (C) The expression levels of Sendai virus backbone (SeV) and transcription factors: KOS (Klf4, Oct3/4, Sox2), Klf4 and cMyc were checked using qPCR. The patient clones reprogrammed using Cytotune 2.0 were free of both viral backbone and transgenes after 13-14 passages (left). Patient clones reprogrammed using the SeVdp(KOSM)302L Sendai virus system were cleared of viral backbone after 25 passages (right). The CT values were normalised to β-actin and are shown relative to positive control (fibroblasts from one day after viral transduction). (D) Flow cytometry results for expression of the iPSC markers Tra-1-60 and Nanog. Frequency of the events in each fluorescence channel (y-axis) versus fluorescence intensity (x-axis) are displayed. Grey peaks show the data of isotype controls, while white peaks show the counts of either Tra-1-60 (FLH-1) or Nanog (FLH-4). More than 85% of the cells of each patient iPSC clone were positive for both pluripotency markers. (E) The karyograms of eight patient iPSC clones as well as two control iPSC lines are shown. All showed normal karyotypes. Amplifications (green), deletions (orange) and loss of heterozygosity regions (grey) are shown alongside the relevant chromosome.. Any changes larger than 1,000,000 nucleotides were considered abnormal. In females the X chromosomes are annotated in grey. Single-copy sex chromosomes are labelled in orange. 
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C (303) A ( showed the wildtype nucleotides at nucleotide 107 in exon 1 and at nucleotide 303 in exon 4 (black arrows). Patients' fibroblasts and iPSC lines of PRKCG01 and PRKCG02 contained the heterozygous an A-to-G transition at nucleotide 107 in exon 1 (red arrows). SCA14-1 and SCA14-2 patient iPSC lines contained a C-to-G transition at nucleotide 303 in exon 4 (red arrows). HDF: human dermal fibroblasts.
Supplementary Figure 4
PDBu-treated iPSCs showed similar cellular phenotypes to PMA-treated cells.
(A) Control and patient iPSCs were immunostained for PKCg before or after treatment with 200nM PDBu. The cell membrane was stained with an antibody against sodium potassium ATPase. Cell nuclei are visualized by Hoechst staining. In unstimulated control iPSCs, PKCg was expressed as small dots in the cytoplasm (white solid arrowhead). After 5 min of PDBu treatment, PKCg was found at the plasma membrane (white hollow arrowheads), and returned to the cytoplasm after 15 min of PDBu treatment (white solid arrowhead). In unstimulated SCA14 iPSCs, large aggregates (white arrows) of PKCg were present in the cytoplasm. PKCg inclusions remained in the cytoplasm (white arrows) throughout the treatment with PDBu. (B) Wildtype and mutant PKCg was negative for ubiquitin staining (white hollow arrowheads) in control and SCA14 iPSCs before and after PMA or PDBu treatment. (C) Control and patient iPSCs were immunostained for PKCg and the autophagosomal marker LC3 before or after treatment with PDBu for 15 min. In control iPSCs, PKCg co-localisation with LC3 (white solid arrowheads) increased upon treatment with PDBu. In untreated SCA14 iPSCs, there was already a significant overlap with LC3 (white solid arrowheads), which did not further increase with PKCg activation. (D) Control and patient iPSCs were immunostained for PKCg and the lysosomal marker LAMP2 before or after treatment with PDBu for 15 min. Co-localisation with LAMP2 is indicated by a solid arrowhead. In control iPSCs, co-localisation of PKCg with LAMP2 increased upon activation. In SCA14 iPSCs, by contrast, lysosomes fused together into larger vesicles enclosing PKCg aggregates (white arrows) in the presence of PDBu. However, the majority of PKCg aggregates did not co-localise with LAMP2-postive lysosomes (white hollow arrowheads). Hoechst stain was used for nuclear staining. Scale bar: 10μm.
